These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12423385)

  • 1. Patients treated with vigabatrin exhibit central visual function loss.
    Hilton EJ; Cubbidge RP; Hosking SL; Betts T; Comaish IF
    Epilepsia; 2002 Nov; 43(11):1351-9. PubMed ID: 12423385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Color vision in epilepsy patients treated with vigabatrin or carbamazepine monotherapy.
    Nousiainen I; Kälviäinen R; Mäntyjärvi M
    Ophthalmology; 2000 May; 107(5):884-8. PubMed ID: 10811079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visual function in epilepsy patients treated with initial valproate monotherapy.
    Sorri I; Rissanen E; Mäntyjärvi M; Kälviäinen R
    Seizure; 2005 Sep; 14(6):367-70. PubMed ID: 15939631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retinal nerve fibre layer attenuation: clinical indicator for vigabatrin toxicity.
    Moseng L; Sæter M; Mørch-Johnsen GH; Hoff JM; Gajda A; Brodtkorb E; Midelfart A
    Acta Ophthalmol; 2011 Aug; 89(5):452-8. PubMed ID: 21251242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Visual function is stable in patients who continue long-term vigabatrin therapy: implications for clinical decision making.
    Paul SR; Krauss GL; Miller NR; Medura MT; Miller TA; Johnson MA
    Epilepsia; 2001 Apr; 42(4):525-30. PubMed ID: 11440348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vigabatrin visual toxicity: evolution and dose dependence.
    Malmgren K; Ben-Menachem E; Frisén L
    Epilepsia; 2001 May; 42(5):609-15. PubMed ID: 11380567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retinal structure and function in vigabatrin-treated adult patients with refractory complex partial seizures.
    Sergott RC; Johnson CA; Laxer KD; Wechsler RT; Cherny K; Whittle J; Feng G; Lee D; Isojarvi J
    Epilepsia; 2016 Oct; 57(10):1634-1642. PubMed ID: 27580566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binasal visual field defects are not specific to vigabatrin.
    Gonzalez P; Sills GJ; Parks S; Kelly K; Stephen LJ; Keating D; Dutton GN; Brodie MJ
    Epilepsy Behav; 2009 Nov; 16(3):521-6. PubMed ID: 19815465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visual field defects in patients taking vigabatrin.
    Midelfart A; Midelfart E; Brodtkorb E
    Acta Ophthalmol Scand; 2000 Oct; 78(5):580-4. PubMed ID: 11037919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy.
    Conway M; Cubbidge RP; Hosking SL
    Epilepsia; 2008 Jan; 49(1):108-16. PubMed ID: 18184224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does the Swedish Interactive Threshold Algorithm (SITA) accurately map visual field loss attributed to vigabatrin?
    Conway ML; Hosking SL; Zhu H; Cubbidge RP
    BMC Ophthalmol; 2014 Dec; 14():166. PubMed ID: 25539569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A controlled study of vigabatrin and visual abnormalities.
    Manuchehri K; Goodman S; Siviter L; Nightingale S
    Br J Ophthalmol; 2000 May; 84(5):499-505. PubMed ID: 10781514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of antiepileptic drugs on visual function, with special reference to Vigabatrin.
    Sorri I
    Acta Ophthalmol Scand; 2002 Jun; 80(3):343-4. PubMed ID: 12059879
    [No Abstract]   [Full Text] [Related]  

  • 14. Vigabatrin-associated visual field defects in children.
    Russell-Eggitt IM; Mackey DA; Taylor DS; Timms C; Walker JW
    Eye (Lond); 2000 Jun; 14 ( Pt 3A)():334-9. PubMed ID: 11026995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Visual field constriction in 91 Finnish children treated with vigabatrin.
    Vanhatalo S; Nousiainen I; Eriksson K; Rantala H; Vainionpää L; Mustonen K; Aärimaa T; Alen R; Aine MR; Byring R; Hirvasniemi A; Nuutila A; Walden T; Ritanen-Mohammed UM; Karttunen-Lewandowski P; Pohjola LM; Kaksonen S; Jurvelin P; Granström ML
    Epilepsia; 2002 Jul; 43(7):748-56. PubMed ID: 12102679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal.
    Newman WD; Tocher K; Acheson JF
    Eye (Lond); 2002 Sep; 16(5):567-71. PubMed ID: 12194070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Examining visual field defects in the paediatric population exposed to vigabatrin.
    Spencer EL; Harding GF
    Doc Ophthalmol; 2003 Nov; 107(3):281-7. PubMed ID: 14711160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Visual field loss in patients with refractory partial epilepsy treated with vigabatrin: final results from an open-label, observational, multicentre study.
    Wild JM; Chiron C; Ahn H; Baulac M; Bursztyn J; Gandolfo E; Goldberg I; Goñi FJ; Mercier F; Nordmann JP; Safran AB; Schiefer U; Perucca E
    CNS Drugs; 2009 Nov; 23(11):965-82. PubMed ID: 19845417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Visual field loss in young children and mentally handicapped adolescents receiving vigabatrin.
    Werth R; Schädler G
    Invest Ophthalmol Vis Sci; 2006 Jul; 47(7):3028-35. PubMed ID: 16799049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is visual field constriction in epilepsy patients treated with vigabatrin reversible?
    Schmidt T; Rüther K; Jokiel B; Pfeiffer S; Tiel-Wilck K; Schmitz B
    J Neurol; 2002 Aug; 249(8):1066-71. PubMed ID: 12195456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.